He said overall, "our outlook remains positive, although we are operating in a period of some uncertainty in the US as the Trump administration prepares to take office" with some commentators pointing to changes in the US healthcare regulatory environment with Donald Trump in the White House.
Sales in North America rose to $69.7 million in the first half from $62.3m a year earlier. Europe, Middle East and Africa posted a drop in sales to $17.9m from $22.8m, while the Asia-Pacific region was little changed at $16.2m.
By revenue type, managed services showed the strongest revenue growth, rising to $25.8m from $21.7m, while perpetual licenses increased to $26m from $22.8m. Implementation services, its biggest revenue generator, fell to $31.2m from $36.3m and support services was little changed at $19.9m from $19.8m.
The gain in North American revenue "was primarily as a result of strong perpetual license sales and steady growth in managed services," the company said. "Our perpetual revenue growth was driven by a strong performance by our Rhapsody activities where demand continues to increase and was assisted by the new agreement with Philips, a leader in healthcare technology."
Rhapsody is Orion's 'foundation' product and is an engine for exchange and acquisition of health data, it says.
As at September 30, its cash balance stood at $24m and its net cash outflow was $33m, reflecting the operating loss and an "unusually large" movement in working capital items. Orion had cash and equivalents of $58.9m as at March 31.